| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Gerhard Rogler | Q64750687 |
| Alexander Navarini | Q40056804 | ||
| Peter Laszlo Lakatos | Q42264535 | ||
| P2093 | author name string | Alain Schoepfer | |
| Michael Scharl | |||
| Stephan R Vavricka | |||
| P2860 | cites work | Infliximab in the treatment of refractory posterior uveitis | Q44516164 |
| Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis | Q44798829 | ||
| Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study | Q45001248 | ||
| Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study | Q45334709 | ||
| Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients | Q45423238 | ||
| Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort | Q45896089 | ||
| Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease | Q46914676 | ||
| The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases | Q46924806 | ||
| Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study | Q46937246 | ||
| Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab. | Q47257324 | ||
| Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease | Q47704363 | ||
| Infliximab as a treatment for recalcitrant pyoderma gangrenosum. | Q48030927 | ||
| A case of fistulizing Crohn's disease and erythema nodosum managed with adalimumab. | Q48505974 | ||
| Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. | Q49206512 | ||
| Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report. | Q51824953 | ||
| Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. | Q53240768 | ||
| Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab. | Q53954491 | ||
| Effect of infliximab on sight-threatening panuveitis in Behçet's disease. | Q54153155 | ||
| Diagnosis and Therapeutic Management of Extra-Intestinal Manifestations of Inflammatory Bowel Disease | Q22241416 | ||
| THE EXTRA-INTESTINAL COMPLICATIONS OF CROHNʼS DISEASE AND ULCERATIVE COLITIS: A STUDY OF 700 PATIENTS | Q22242792 | ||
| Primary Sclerosing Cholangitis, Inflammatory Bowel Disease, and Colon Cancer | Q22250922 | ||
| Cutaneous manifestations of gastrointestinal disease | Q22252408 | ||
| Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease | Q28194972 | ||
| Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort | Q28239892 | ||
| Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis | Q28290468 | ||
| Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease | Q32099443 | ||
| Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis | Q33222422 | ||
| Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease | Q33825052 | ||
| Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions | Q33835522 | ||
| Extraintestinal manifestations and complications in inflammatory bowel diseases | Q33866998 | ||
| Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management | Q33916356 | ||
| The histocompatibility antigen (HL-A 27) and disease | Q33987304 | ||
| Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis | Q34097072 | ||
| Current use of biologicals for the treatment of spondyloarthropathies | Q34240751 | ||
| Muscoloskeletal manifestations in inflammatory bowel disease | Q34295390 | ||
| Clinical patterns of familial inflammatory bowel disease | Q34409700 | ||
| Genetic markers may predict disease behavior in patients with ulcerative colitis | Q34428379 | ||
| Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis | Q34465376 | ||
| Inflammatory bowel disease and spondylarthropathy | Q34474693 | ||
| Extraintestinal manifestations in inflammatory bowel disease. | Q34488386 | ||
| Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis | Q34524586 | ||
| Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease | Q34636098 | ||
| Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes | Q34800055 | ||
| Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history | Q35349708 | ||
| Important cutaneous manifestations of inflammatory bowel disease | Q35522694 | ||
| Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations | Q35553741 | ||
| Extraintestinal complications of inflammatory bowel disease | Q35577416 | ||
| Anti-TNF-alpha therapy for sight threatening uveitis | Q35593155 | ||
| Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. | Q55042580 | ||
| Anti-TNF- therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients | Q57767895 | ||
| Arthritic manifestations of inflammatory bowel disease | Q68144522 | ||
| The production and characterization of monoclonal antibodies to a human colonic antigen associated with ulcerative colitis: cellular localization of the antigen by using the monoclonal antibody | Q68155589 | ||
| Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease | Q68828599 | ||
| Clinicopathologic features of the syndrome of primary sclerosing cholangitis | Q71266771 | ||
| Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients | Q71603762 | ||
| Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis | Q72349099 | ||
| Oral metronidazole, an effective treatment for Sweet's syndrome in a patient with associated inflammatory bowel disease | Q72355003 | ||
| Ocular manifestations of inflammatory bowel disease | Q72531760 | ||
| Clinical features and treatment of peristomal pyoderma gangrenosum | Q72989601 | ||
| Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group | Q73090826 | ||
| Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms | Q73299268 | ||
| Infliximab for peristomal pyoderma gangrenosum | Q73404292 | ||
| Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease | Q73520735 | ||
| Dermatologic manifestations of Crohn disease in children: response to infliximab | Q73713061 | ||
| The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study | Q73792791 | ||
| Pyoderma gangrenosum and its treatment | Q73979949 | ||
| Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease | Q74246313 | ||
| Pyoderma gangrenosum | Q74282444 | ||
| Extraintestinal manifestations of inflammatory bowel disease | Q74474697 | ||
| Clinical use of Infliximab in Crohn's disease: the Edinburgh experience | Q74530732 | ||
| Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis | Q74628493 | ||
| Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum | Q74636928 | ||
| Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab | Q77694270 | ||
| [Sweet's syndrome and erythema nodosum associated with Crohn's disease treated by infliximab] | Q78021485 | ||
| Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab | Q78357605 | ||
| Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease | Q78389064 | ||
| Crohn's disease arthritis treated with infliximab: an open trial in four patients | Q79235205 | ||
| Treatment of chronic erythema nodosum with infliximab | Q79238420 | ||
| Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease | Q79680142 | ||
| Refractory chronic erythema nodosum successfully treated with adalimumab | Q79797493 | ||
| Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study | Q80410995 | ||
| The effect of infliximab on extraintestinal manifestations of Crohn's disease | Q80447239 | ||
| Treatment of pyoderma gangrenosum with infliximab in Crohn's disease | Q80853884 | ||
| [Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis] | Q81207580 | ||
| Primary sclerosing cholangitis | Q81326220 | ||
| Adalimumab for treatment of pyoderma gangrenosum | Q81397418 | ||
| Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease | Q81399056 | ||
| Extraintestinal manifestations of inflammatory bowel disease | Q81574494 | ||
| Azathioprine-induced Sweet's syndrome in Crohn's disease | Q81632826 | ||
| Skin manifestations of inflammatory bowel disease | Q81669207 | ||
| Anti-TNF therapies in the management of acute and chronic uveitis | Q82856455 | ||
| Favorable response to high-dose infliximab for refractory childhood uveitis | Q82869656 | ||
| Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN) | Q83162560 | ||
| Leucocytoclastic vasculitis in severe ulcerative colitis | Q84248982 | ||
| Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease | Q85357712 | ||
| Periodontitis and gingivitis in inflammatory bowel disease: a case-control study | Q86702997 | ||
| Hepatobiliary manifestations of inflammatory bowel disease | Q87977887 | ||
| PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis | Q35597119 | ||
| Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. | Q35760415 | ||
| Adalimumab in the therapy of uveitis in childhood | Q35763157 | ||
| Ocular manifestations of inflammatory bowel disease | Q35787601 | ||
| Management of peristomal pyoderma gangrenosum | Q36114489 | ||
| Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept | Q36211828 | ||
| Retrospective case review of pediatric patients with uveitis treated with infliximab | Q36365819 | ||
| Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. | Q36388536 | ||
| Adalimumab therapy for recalcitrant pyoderma gangrenosum | Q36675139 | ||
| Erythema nodosum progressing to pyoderma gangrenosum as a complication of Crohn's disease | Q36705230 | ||
| Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review | Q36933111 | ||
| Ulcerative colitis and Sweet's syndrome: a case report and review of the literature | Q37114666 | ||
| Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone | Q37192685 | ||
| Rheumatic manifestations of inflammatory bowel disease | Q37445601 | ||
| Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? | Q37587778 | ||
| Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease | Q37701805 | ||
| Relationship of inflammatory bowel disease and primary sclerosing cholangitis | Q37755868 | ||
| Pyoderma gangraenosum | Q37805310 | ||
| IBD and arthropathies: a practical approach to its diagnosis and management | Q37873223 | ||
| Sweet's syndrome: a clinicopathologic review of twenty-nine cases | Q37961702 | ||
| Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics | Q38007126 | ||
| Treatment of extraintestinal manifestations in inflammatory bowel disease | Q38050884 | ||
| Extraintestinal manifestations and complications in IBD. | Q38120146 | ||
| Biologics for extraintestinal manifestations of IBD. | Q38246888 | ||
| Neutrophilic vascular reactions | Q39549375 | ||
| Sweet's syndrome associated with Crohn's disease. | Q40780629 | ||
| Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort | Q40893795 | ||
| Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. | Q40910814 | ||
| Treatment of pyoderma gangrenosum | Q40997108 | ||
| A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody | Q41027381 | ||
| The sacroiliac joint in the spondyloarthropathies. | Q41157885 | ||
| A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody | Q41199465 | ||
| Factors influencing the relapse of patients with inflammatory bowel disease. | Q41659082 | ||
| National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications | Q41735882 | ||
| Sweet's syndrome and pyoderma gangrenosum associated with ulcerative colitis. | Q42034663 | ||
| Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis. | Q43066415 | ||
| Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27) | Q43248978 | ||
| Clinical patterns in Crohn's disease: a statistical study of 615 cases | Q43494034 | ||
| Extracolonic diagnoses in ulcerative colitis: an epidemiological study. | Q43527431 | ||
| An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia | Q44465348 | ||
| P433 | issue | 8 | |
| P921 | main subject | inflammation | Q101991 |
| eye disease | Q3041498 | ||
| musculoskeletal disorder | Q4116663 | ||
| inflammatory bowel diseases | Q917447 | ||
| liver disease | Q929737 | ||
| skin disease | Q949302 | ||
| biliary tract disease | Q18558210 | ||
| P304 | page(s) | 1982-1992 | |
| P577 | publication date | 2015-08-01 | |
| P1433 | published in | Inflammatory Bowel Diseases | Q15749161 |
| P1476 | title | Extraintestinal Manifestations of Inflammatory Bowel Disease. | |
| P478 | volume | 21 |
| Q37670529 | A Potential Role of Salmonella Infection in the Onset of Inflammatory Bowel Diseases |
| Q37621044 | A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis |
| Q64255863 | Acute Myopericarditis with Crohn's Disease Flare-up |
| Q36140024 | Altered Markers of Brain Development in Crohn's Disease with Extraintestinal Manifestations - A Pilot Study |
| Q57471139 | An Increased Abundance of Clostridiaceae Characterizes Arthritis in Inflammatory Bowel Disease and Rheumatoid Arthritis: A Cross-sectional Study |
| Q90346725 | An unexpected and rare complication after endovenous laser ablation: Pyoderma gangrenosum |
| Q38814948 | Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study |
| Q96231807 | Anti-TNF-induced lupus in patients with inflammatory bowel disease |
| Q91710473 | Antitumor Drug Combretastatin-A4 Phosphate Aggravates the Symptoms of Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice |
| Q64090602 | Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study |
| Q47392986 | Association of Inflammatory Bowel Disease with Arthritis: Evidence from In Silico Gene Expression Patterns and Network Topological Analysis. |
| Q61818531 | Cardiovascular Manifestations of Inflammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies |
| Q37540172 | Care of inflammatory bowel disease patients in remission |
| Q90733799 | Cell membrane and bioactive factors derived from mesenchymal stromal cells: Cell-free based therapy for inflammatory bowel diseases |
| Q92784032 | Chloramphenicol Resurrected: A Journey from Antibiotic Resistance in Eye Infections to Biofilm and Ocular Microbiota |
| Q99404850 | Circadian Host-Microbiome Interactions in Immunity |
| Q48250204 | Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease |
| Q37116956 | Clinical features of Crohn disease concomitant with ankylosing spondylitis: A preliminary single-center study |
| Q91692236 | Comorbidities in adolescents with inflammatory bowel disease: findings from a population-based cohort study |
| Q37328410 | Cytokine and Chemokine Profile in Amicrobial Pustulosis of the Folds: Evidence for Autoinflammation |
| Q39377846 | DNA methylation patterns in ulcerative colitis-associated cancer: a systematic review |
| Q48094935 | Editorial: co-existing immune-mediated disease in inflammatory bowel diseases - a new disease severity indicator? Author's reply |
| Q55441867 | Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. |
| Q92003948 | Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials |
| Q48329328 | Efficacy of cytapheresis for remission induction and dermatological manifestations of ulcerative colitis |
| Q41677436 | Experimental colitis delays and reduces the severity of collagen-induced arthritis in mice |
| Q64052784 | Extraintestinal Manifestations of Inflammatory Bowel Disease |
| Q99596645 | Extraintestinal Manifestations of Inflammatory Bowel Disease in Middle Eastern Patients |
| Q47952446 | Gut-brain actions underlying comorbid anxiety and depression associated with inflammatory bowel disease |
| Q39077398 | Host-Microbiota Interactions Shape Local and Systemic Inflammatory Diseases |
| Q90350371 | Identifying Crohn's disease signal from variome analysis |
| Q99403369 | Inactive matrix Gla protein is elevated in patients with inflammatory bowel disease |
| Q92423987 | Inflammatory bowel disease: Looking beyond the tract |
| Q89839206 | Inflammatory bowel disease: between genetics and microbiota |
| Q42396854 | Lung injury as an extra-intestinal manifestation of inflammatory bowel disease |
| Q92051810 | Mechanisms Underlying Bone Loss Associated with Gut Inflammation |
| Q47762490 | Migraine prevalence in inflammatory bowel disease patients: A tertiary-care centre cross-sectional study |
| Q35977019 | Mucosal and salivary microbiota associated with recurrent aphthous stomatitis |
| Q49289627 | Nutrition and Liver Disease. |
| Q61809759 | Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study |
| Q33819519 | Ophthalmologic manifestations in patients with inflammatory bowel disease |
| Q47754415 | Oral Delivery of Nanoparticles Loaded With Ginger Active Compound, 6-Shogaol, Attenuates Ulcerative Colitis and Promotes Wound Healing in a Murine Model of Ulcerative Colitis. |
| Q39169825 | Oral Pyoderma Gangrenosum: Diagnosis, Treatment and Challenges: A Systematic Review |
| Q26739055 | Oral pathology in inflammatory bowel disease |
| Q36058941 | Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account. |
| Q58754774 | Pancreatic Involvement in Inflammatory Bowel Disease: A Review |
| Q59809265 | Peripheral Lymphocytes of Patients with Inflammatory Bowel Disease Have Altered Concentrations of Key Apoptosis Players: Preliminary Results |
| Q38966995 | Pouchitis after ileal pouch-anal anastomosis in ulcerative colitis: Diagnosis, management, risk factors, and incidence. |
| Q57211266 | Prevalence of extraintestinal manifestations in Korean inflammatory bowel disease patients |
| Q45338711 | Preventing disability in inflammatory bowel disease |
| Q64068877 | Recurrent Inflammatory Myositis as an Extra-Intestinal Manifestation of Dormant Ulcerative Colitis in a Patient on Long-Term Mesalamine |
| Q36719865 | Risk factors for complications in patients with ulcerative colitis |
| Q90372230 | Serum cytokine, chemokine, and growth factor profiles and their modulation in inflammatory bowel disease |
| Q99234081 | Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease |
| Q90156769 | Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases? |
| Q44390503 | Skin Manifestations of Inflammatory Bowel Disease |
| Q48332071 | Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides. |
| Q92712288 | Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors - A cross-sectional study |
| Q61451061 | Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis |
| Q102048564 | Splenic erythroid progenitors decrease TNFα production by macrophages and reduce systemic inflammation in a mouse model of T cell-induced colitis |
| Q40121922 | Sweet's syndrome complicating ulcerative colitis: a rare association |
| Q92615756 | Synergistic protection of astragalus polysaccharides and matrine against ulcerative colitis and associated lung injury in rats |
| Q89736698 | Targeting NF-κB pathway for treating ulcerative colitis: comprehensive regulatory characteristics of Chinese medicines |
| Q46443053 | The Anti-Inflammatory Effect and Intestinal Barrier Protection of HU210 Differentially Depend on TLR4 Signaling in Dextran Sulfate Sodium-Induced Murine Colitis |
| Q93081048 | The Etiology of Pancreatic Manifestations in Patients with Inflammatory Bowel Disease |
| Q91789251 | The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD |
| Q90449784 | The Spectrum of Extra-intestinal Manifestation of Crohn's Disease |
| Q64080168 | The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort |
| Q64262341 | The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults |
| Q52603361 | Therapy for Crohn's Disease: a Review of Recent Developments. |
| Q64064682 | Transitions of care across hospital settings in patients with inflammatory bowel disease |
| Q92858311 | Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study |
| Q47095956 | Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. |
| Q56978743 | Visions of Eye Commensals: The Known and the Unknown About How the Microbiome Affects Eye Disease |
| Q90145538 | [From Axial Spondyloarthritis to Osteoporosis - Spectrum of Skeletal Involvement in Inflammatory Bowel Diseases] |
Search more.